**Introduction**

In preclinical studies, FT576 combined with the anti-CD38 mAb daratumumab demonstrated these modalities are designed to enhance potency and persistence and to enable off-the-shelf natural killer (NK) cell therapies may offer an improved therapeutic profile and broader patient access than autologous CAR-T cell therapies.

**Methods**

FT576 is a first-of-kind, multiplexed-engineered, BCMA-targeted CAR NK cell therapy developed using a dual-targeting strategy. Preclinical data from an ongoing Phase 1 trial is presented below.

**Results**

Anti-tumor Activity

- Of the 8 evaluable patients, 3 patients had a decrease in their myeloma disease burden within 14 days with 2 subjects achieving a confirmed objective response.
- 1 patient who had been treated with 5 prior lines of therapy and was triple refractory to an IMiD, a PI, and an anti-CD38 mAb achieved a partial response.
- Evidence of FT576 activity further demonstrated by treatment-induced decreases in soluble IL-6R cell membrane antigen (sIL-6Ra), including in patients with objective response (ORR) seen across regimens.

**Conclusions & Future Directions**

- Administration of a single dose of FT576 as monotherapy and in combination with daratumumab is safe and well-tolerated: there were no events of grade 3 or 4 CRS, G4N, or GvHD.
- 2 patients had Grade 3 treatment-emergent AEs related to FT576: 1 patient with Grade 3 diarrhea, and 1 patient with 2 episodes of Grades 3 through 4 neutropenia and 3 episodes of Grade 3 anemia.
- All episodes of Grade 3 treatment-emergent AEs related to FT576 resolved.
- There were no serious AEs related to FT576.
- There were no study discontinuations or deaths due to treatment-emergent AEs.

**Safety**

- No dose-limiting toxicities or reoccurrences of any grade of CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), or graft versus host disease (GVHD) were observed.
- 2 patients had Grade 3 treatment-emergent adverse events (AEs) related to FT576:
  - 1 patient had Grade 3 diarrhea.
  - 1 patient experienced 2 episodes of Grades 3 through 4 neutropenia and 3 episodes of Grade 3 anemia.
  - Grade 3 treatment-emergent AEs not related to FT576 in 2 patients included: anemia, neutropenia, and white blood cell decreased.

**Tolerability**

- There were no study discontinuations or deaths due to treatment-emergent AEs.